2020. Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s72. DOI:https://doi.org/10.25251/skin.4.supp.72.